Express Scripts lets the genie out the bottle!!!!

When Jim Chanos Speaks – Citron Listens.

First Enron, Then Valeant, Now Mallinckrodt.

Mallinckrodt is the most reviled company in the pharmaceutical industry. Its unsavory business practices have only survived in the “post Valeant” era because of the direct business support of Express Scripts, their “co-conspirator”.

Two weeks ago at the SALT conference in Las Vegas, legendary short seller Jim Chanos described this unholy alliance, likening the Express Scripts companies’ role to Valeant’s Philidor.

Express Scripts has been taking so much heat from investors it was forced to throw Mallinckrodt under the bus. But a typo prevented Wall Street from taking full notice of this sea change in Mallinckrodt’s fortunes.

/wp-content/uploads/2017/06/freatured-mall-3.jpg500900Citron Research/wp-content/uploads/2017/05/CitronLogo2017-350x65-1.pngCitron Research2017-06-05 14:10:242017-06-05 16:12:56Citron Provides New Proof Why Mallinckrodt is on its way to ZERO

To Reveal the True Value of Exact Sciences (NASDAQ:EXAS) Listen to the Highly Respected Company that is the ”Science” behind Exact Sciences

Short Term Target Reaffirmed at $20 … Long Term Looks Dire

Citron is surprised that neither investors nor analysts properly analyzed the important disclosure from Exact on April 27th. Citron notes that the company did not issue a PR for this transaction, but suggests that all investors seeking insight into the company’s prospects had better consider it carefully.

Every Man and Woman Over The Age of 50 MUST read this report from Citron Research

Short term target: $20.

3 to 5 Years: Likely Single Digit, Potential 0.

Exact Sciences (NASDAQ:EXAS) pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it. That is why this $4 billion company is mainly owned by passive investing ETFs or other healthcare baskets.

More importantly, as Citron will expose, the key metrics not disclosed by Exact Sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.

This stock is a poster child for what goes wrong when Wall Street gets ahold of a health care concept with no discrimination for whether its good or bad medicine.

Short Term Price Target = $80

In our first report Citron referred to FleetCor (NYSE:FLT) as “FeeCor” and “FleeceCor”. The bulls defended the company, claiming FleetCor’s customer fees are legal, not egregious, and most of all are sustainable.

In this report Citron clarifies the illegality of FleetCor’s corporate practices, and the lengths the analyst community goes to in defending them.

/wp-content/uploads/2017/03/FleetCor-Image-Scam-Key.jpg305457Citron Research/wp-content/uploads/2017/05/CitronLogo2017-350x65-1.pngCitron Research2017-04-27 16:59:532017-05-29 04:46:06Citron Exposes the Dirty Illegal Secrets of FleetCor, and Proof the Company is Already in Cover-Up Mode